- Home
- PRTC vs AMPX Comparison
PRTC vs AMPX Comparison
Compare PRTC & AMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- AMPX
- Stock Information
- Founded
- PRTC 2015
- AMPX 2008
- Country
- PRTC United States
- AMPX United States
- Employees
- PRTC N/A
- AMPX N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- AMPX Industrial Machinery/Components
- Sector
- PRTC Health Care
- AMPX Miscellaneous
- Exchange
- PRTC Nasdaq
- AMPX Nasdaq
- Market Cap
- PRTC 439.8M
- AMPX 514.7M
- IPO Year
- PRTC N/A
- AMPX N/A
- Fundamental
- Price
- PRTC N/A
- AMPX $4.68
- Analyst Decision
- PRTC Buy
- AMPX Strong Buy
- Analyst Count
- PRTC 1
- AMPX 7
- Target Price
- PRTC $45.00
- AMPX $8.71
- AVG Volume (30 Days)
- PRTC 5.9K
- AMPX 5.9M
- Earning Date
- PRTC 08-27-2025
- AMPX 08-07-2025
- Dividend Yield
- PRTC N/A
- AMPX N/A
- EPS Growth
- PRTC N/A
- AMPX N/A
- EPS
- PRTC 0.21
- AMPX N/A
- Revenue
- PRTC $4,828,000.00
- AMPX $33,115,000.00
- Revenue This Year
- PRTC $35.98
- AMPX $167.22
- Revenue Next Year
- PRTC $115.38
- AMPX $208.02
- P/E Ratio
- PRTC $7.93
- AMPX N/A
- Revenue Growth
- PRTC 44.98
- AMPX 209.20
- 52 Week Low
- PRTC $13.30
- AMPX $0.61
- 52 Week High
- PRTC $25.00
- AMPX $4.83
- Technical
- Relative Strength Index (RSI)
- PRTC 43.39
- AMPX 68.15
- Support Level
- PRTC $16.50
- AMPX $3.80
- Resistance Level
- PRTC $18.40
- AMPX $4.35
- Average True Range (ATR)
- PRTC 0.45
- AMPX 0.36
- MACD
- PRTC -0.17
- AMPX 0.05
- Stochastic Oscillator
- PRTC 20.88
- AMPX 89.29
About PRTC PureTech Health plc
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites.